Innovative Immunotherapy Combo Tests IDO Inhibitor in Melanoma Trial

Ariela Katz
Published: Monday, Mar 20, 2017
Omid Hamid, MD

Omid Hamid, MD
Investigators are looking into a novel immunotherapy combination that pairs the first-in-class IDO1 inhibitor epacadostat (INCB024360) with the checkpoint blockade agent pembrolizumab (Keytruda) in patients with unresectable or metastatic melanoma.


Figure. Epacadostat Combination in Melanoma

Figure. Epacadostat Combination in Melanoma

CT indicates computed tomography; ECOG, Eastern Cooperative Oncology Group; MRI, magnetic resonance imaging; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.
The study is open to adult patients with unresectable stage III or stage IV melanoma not amenable to local treatment. Patients who have received prior systemic treatment for their disease, particularly therapy directed at the PD-1/PD-L1 pathway, CD137, or IDO1 are excluded from the trial. Anti-CTLA-4 therapy is permitted in the adjuvant setting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication